Long-term follow-up of Eque-cel (Equecabtagene Autoleucel) for multiple myeloma
Official title: Long-term Follow-up Registry Study of Equecabtagene Autoleucel Injection
Run by Nanjing IASO Biotechnology Co., Ltd. · NCT07028970 · Data updated 2026-11-12
This follow-up will see how people with multiple myeloma who previously received Eque-cel (Equecabtagene Autoleucel) are doing over time.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 1500 (estimated) |
| Sponsor | Nanjing IASO Biotechnology Co., Ltd. Industry-sponsored |
| Drugs / interventions | CAR-T |
| Locations | 6 sites (Beijing and 5 other locations) |
| Status | Recruiting |
| Started | December 15, 2024 |
| Main results expected | December 2040 |
| Study ends | December 2043 |
| Registry record updated | June 19, 2025 |
| Trial ID | NCT07028970 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are people with multiple myeloma who have already received Eque-cel in a prior clinical or real-world setting and who can provide informed consent.
✕Probably not a fit
Patients who have not received Eque-cel or who received another lentiviral-vector cell or gene therapy after their Eque-cel infusion (and before signing consent) are unlikely to benefit from this registry.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This multicenter, open-label, single-arm registry enrolls people who have already received Equecabtagene Autoleucel (Eque-cel) to track long-term outcomes. Participants will be followed periodically to collect safety data, clinical status, and measurements of CAR-T cell persistence, with no new investigational interventions administered. The initial post-marketing follow-up period is two years for pre-marketing studies, while national technical guidance recommends extended monitoring (up to 15 years) to detect late effects related to genomic integration. Data will be used to identify long-term risks and differences in safety across populations to inform the product's benefit–risk profile.
Why it matters
Potential benefit: If successful, the registry could reveal late side effects and how long Eque-cel benefits last, helping doctors manage long-term care and improve patient safety.
How similar studies have gone: Other CAR-T products for multiple myeloma have published long-term follow-up showing durable responses and safety monitoring, but long-term data specific to Eque-cel remain limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: \- 1.Received Equecabtagene Autoleucel Injection treatment; 2.For those who participated in pre-marketing clinical studies or post-marketing real-world studies, must have completed or withdrawn from the original study; 3.Voluntary signing of an informed consent form approved by the ethics committee. Exclusion Criteria: * 1\. Receipt of another lentiviral vector-based cell or gene therapy (either commercialized product or investigational product in a clinical tiral) between the infution of Equecabtagene Autoleucel Injection and the signing informed consent.
Where it's running
-
Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences
Tianjin, China Recruiting -
Tianjin Medical University General Hospital
Tianjin, China Recruiting -
Peking University First Hospital
Beijing, China Not yet recruiting -
People's Hospital of Peking Universit
Beijing, China Not yet recruiting -
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, China Not yet recruiting -
Henan Cancer Hospital Affilated Cancer Hospital of Zhengzhou University
Zhengzhou, China Not yet recruiting
Study contacts
- Principal investigator: Jian Li, PhD — Peking Union Medical College Hospital
- Study coordinator: Wen Ye
- Email: wen.ye@iasobio.com
- Phone: +86 025-58287610
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
6MW5311 in adults with relapsed or refractory blood cancers
This study tests increasing doses of 6MW5311 in adults with multiple myeloma, AML, or CMML to see if it is safe and tolerable and to find a suitable dose for later studies.
-
Tailored exercise program to improve quality of life for adults with hematologic cancers
This pilot trial tests a personalized 16-week exercise program to see if it’s feasible and helpful for adults with acute myeloid leukemia, lymphoma, or multiple myeloma after first-line treatment.
-
Aspirin vs. rivaroxaban for blood clot prevention in newly diagnosed multiple myeloma
In newly diagnosed multiple myeloma patients on IMiD-based therapy, this study tests whether aspirin or rivaroxaban is better at preventing blood clots.
-
Exercise phenotyping before chemotherapy in newly diagnosed multiple myeloma
This observational study tests whether some newly diagnosed multiple myeloma patients with normal resting heart function already show limited exercise capacity, and whether that limitation relates to subtle heart tissue changes and future heart-related outcomes.
-
SMS text check-ins to track symptoms for people with plasma cell disorders
This study tests whether daily SMS symptom prompts are feasible and acceptable for adults starting treatment for multiple myeloma or AL amyloidosis.
-
Cevostamab with Pomalidomide and Dexamethasone after BCMA-directed CAR T therapy in multiple myeloma
This study tests if Cevostamab combined with pomalidomide and dexamethasone can help people with multiple myeloma who have already had CAR T therapy and several prior treatments.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.